QURE

uniQure N.V. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website uniqure.com
Employees(FY) 501
ISIN NL0010696654

Performance

+12.75%

+191.75%

+199.47%

+271.55%

+150.81%

YTD

+172.33%

Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Advanced Technical Analysis

Technical Analysis of QURE 2024-12-20

The stock exhibits a strong bullish sentiment with a Moving Average Score of 96, indicating robust upward momentum, while the Technical Score of 76 further supports this positive outlook. However, the Oscillators Score of 56 suggests a neutral stance, indicating potential consolidation or a pause in the upward trend, which investors should monit...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of QURE

Stock Rank

Recent News & Updates

2024-12-17 07:20
uniQure price target raised to $32 from $12 at Stifel(TipRanks)
2024-12-15 04:31
Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?(Motley Fool)
2024-12-12 16:57
Uniqure Insider Sold Shares Worth $1,503,000, According to a Recent SEC Filing(MT Newswires)
2024-12-11 10:02
QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug(Zacks)
2024-12-11 09:55
Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More(Zacks)
2024-12-11 07:29
RBC Raises Price Target on uniQure to $20 From $14, Keeps Outperform, Speculative Risk(MT Newswires)
2024-12-10 17:11
UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug(Investor's Business Daily)
2024-12-10 14:37
UniQure Gets Rating Upgrade From Wells Fargo After Agreement With FDA -- Shares Continue Rally(MT Newswires)
2024-12-10 07:56
UniQure Says Aligned With FDA on Approval Pathway for Huntington's Disease Drug; Shares Jump(MT Newswires)
2024-12-10 07:07
UniQure shares soar on chance of speedy approval for Huntington’s therapy(BioPharma Dive)
2024-12-10 07:05
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease(GlobeNewswire)
2024-12-09 20:34
UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug(Yahoo Finance)
2024-12-09 18:05
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease(Globenewswire)
2024-12-07 07:08
Is uniQure N.V. (NASDAQ:QURE) Trading At A 39% Discount?(Simply Wall St.)
2024-11-28 20:55
Wall Street Analysts Think uniQure (QURE) Could Surge 228.07%: Read This Before Placing a Bet(Yahoo Finance)
2024-11-27 23:00
What Makes uniQure (QURE) a New Buy Stock(Yahoo Finance)
2024-11-20 18:05
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy(Globenewswire)
2024-11-07 20:55
Wall Street Analysts Believe uniQure (QURE) Could Rally 169.18%: Here's is How to Trade(Yahoo Finance)
2024-11-04 19:30
UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates(Yahoo Finance)
2024-11-04 18:26
UniQure: Q3 Earnings Snapshot(Yahoo Finance)
2024-11-04 18:05
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress(Globenewswire)
2024-10-28 22:01
UniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release(Yahoo Finance)
2024-10-18 03:03
State Street Corp's Strategic Reduction in uniQure NV Holdings(Yahoo Finance)
2024-10-14 19:05
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment of SOD1-ALS(Yahoo Finance)
2024-10-14 19:05
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS(Globenewswire)
2024-09-22 19:05
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease(Globenewswire)
2024-08-14 19:05
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease(Globenewswire)
2024-08-01 00:51
UniQure restructuring to claim 300 jobs(Yahoo Finance)
2024-07-31 20:25
UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates(Yahoo Finance)
2024-07-31 19:22
UniQure: Q2 Earnings Snapshot(Yahoo Finance)

Page 1 of 6

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.